Alopecia Areata: current and emerging treatment options
Alopecia areata is an autoimmune condition that can cause patchy hair loss anywhere on the body, though it most often affects the scalp. The medical name for baldness or hair loss is "alopecia," and "areata" denotes that it happens in small, sporadic patches. Loss of immunological privilege in hair follicles causes the condition, and CD8+NKG2D+ T cells release cytokines such as interleukin-15 (IL-15) and interferon-gamma (IFN-γ). They cause inflammation and disrupt normal hair growth by activating the JAK-STAT pathway. The severity of the illness determines the course of treatment. For localised AA, topical and intralesional corticosteroids—especially intralesional triamcinolone—remain widely utilised. Adjunctive treatments include topical minoxidil, bimatoprost, latanoprost, and anthralin. Although side effects and frequent clinic visits may restrict their usage, contact immunotherapy using diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) may be considered for widespread disease. JAK inhibitors have emerged from our growing understanding of the JAK-STAT pathway and represent a significant development in the treatment of AA. The JAK1/JAK2 inhibitor baricitinib, which is licensed for severe AA in adults, showed notable scalp hair regeneration in phase 3 trials. The JAK3/TEC-family kinase inhibitor ritlecitinib has shown sustained long-term effects and is approved for use in adults and adolescents ≥12 years of age. SALT scores have also significantly improved with the specific JAK1/JAK2 inhibitor deuruxolitinib. Other medications, including upadacitinib, brepocitinib, and tofacitinib, are being studied or utilised in specific contexts. Upper respiratory infections, acne, headaches, and test abnormalities such as elevated cholesterol and creatine phosphokinase are common side effects of JAK inhibitors. It is advised to keep an eye on blood counts, liver enzymes, cholesterol, and infection status. Despite these developments, long-term safety, non-response, relapse upon therapy discontinuation, and cost continue to be significant obstacles. New immune-targeted therapies and customised maintenance therapy are the key topics of future research. All things considered, patients with severe AA now have a far wider range of treatment options due to targeted JAK inhibition.
Authors
- Fahima Ayisha Aathika
- Neha
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24423151
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00